ResMed Inc
(ASX:RMD) is set to sell Rhinomed Limited’s
(ASX:RNO) snoring technology online.
The US based sleep disorder company will sell Rhinomed’s Mute snoring technology into the UK market.
The company says the over the counter product has shown solid signs of effectively reducing snoring and improving sleep quality.
Mute is registered with the FDA, Australian regulators and has the EU CE mark.
Rhinomed CEO Michael Johnson says the company’s delighted to be working with Resmed which is focussed on innovative products in the sleep space.
Resmed reported a net profit of $213 million for the first half of the 2015 financial year.
